Sotagliflozin is a medicine for people with type 2 diabetes that improves blood sugar and blood pressure. The medicine also reduces the risk of worsening of heart vessels and kidney diseases. And now a new study suggests it may have the same beneficial effects on the heart and kidneys of people with type 1 diabetes.
Listen to Elisabeth Stougaard, doctor and PhD at Steno Diabetes Center Copenhagen tell much more in this second episode of The Diabetes Researchers.
Diabetes researchers are published in a collaboration between the seven Steno Diabetes Centers. All podcasts are in Danish.